1. |
El-Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother, 2009 ,64: 229-238.
|
2. |
Ray GT, Baxter R, DeLorenze GN. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa, Clin Infect Dis, 2005, 41: 441-449.
|
3. |
Fluit AC, Visser MR, Schmitz FJ. Molecular Detection of Antimicrobial Resistance. Clin Microbiol Rev, 2001, 14: 836-871.
|
4. |
中華醫學會呼吸病學分會. 醫院內獲得性支氣管-肺感染診斷標準( 試行草案) . 實用內科雜志, 1990, 10: 540.
|
5. |
Strateva T, Yordanov D. Pseudomonas aeruginosa--a phenomenon of bacterial resistance. JMed Microbiol, 2009, 58: 1133-1148.
|
6. |
Sekiguchi JI, Asagi T, Miyoshi-Akiyama T, et al. Outbreaks of Multidrug-Resistant Pseudomonas aeruginosa in Community Hospitals in Japan. J Clin Microbiol, 2007, 45: 979-989.
|
7. |
Takenouchi T, Sakagawa E, Sugawara M. Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones. Antimicrob Agents chemother, 1999, 43: 406-409.
|
8. |
Shen LL. Quinolone interactions with DNA and DNA gyrase.Methods Mol Biol, 2001, 95: 171-184.
|
9. |
MouneimnēH, Robert J, Jarlier V, et al. Type II topoisomerase Mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother, 1999, 43: 62-66.
|